94 related articles for article (PubMed ID: 18036567)
21. Ligand-induced structural transitions in ErbB receptor extracellular domains.
Dawson JP; Bu Z; Lemmon MA
Structure; 2007 Aug; 15(8):942-54. PubMed ID: 17697999
[TBL] [Abstract][Full Text] [Related]
22. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
[TBL] [Abstract][Full Text] [Related]
23. The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation.
Kani K; Park E; Landgraf R
Biochemistry; 2005 Dec; 44(48):15842-57. PubMed ID: 16313187
[TBL] [Abstract][Full Text] [Related]
24. Dimerization drives EGFR endocytosis through two sets of compatible endocytic codes.
Wang Q; Chen X; Wang Z
J Cell Sci; 2015 Mar; 128(5):935-50. PubMed ID: 25588832
[TBL] [Abstract][Full Text] [Related]
25. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
[TBL] [Abstract][Full Text] [Related]
27. The neuregulin-I/ErbB signaling system in development and disease.
Britsch S
Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
[TBL] [Abstract][Full Text] [Related]
28. Mapping ErbB receptors on breast cancer cell membranes during signal transduction.
Yang S; Raymond-Stintz MA; Ying W; Zhang J; Lidke DS; Steinberg SL; Williams L; Oliver JM; Wilson BS
J Cell Sci; 2007 Aug; 120(Pt 16):2763-73. PubMed ID: 17652160
[TBL] [Abstract][Full Text] [Related]
29. N-glycan on N262 of FGFR3 regulates the intracellular localization and phosphorylation of the receptor.
Hashimoto U; Fujitani N; Uehara Y; Okamoto H; Saitou A; Ito F; Ariki S; Shiratsuchi A; Hasegawa Y; Takahashi M
Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130565. PubMed ID: 38244702
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor mutant with wild-type affinity for both ErbB1 and ErbB3.
Wingens M; Jacobs-Oomen S; van der Woning SP; Stortelers C; van Zoelen EJ
Biochemistry; 2006 Apr; 45(14):4703-10. PubMed ID: 16584205
[TBL] [Abstract][Full Text] [Related]
31. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
[TBL] [Abstract][Full Text] [Related]
32. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface.
Berger MB; Mendrola JM; Lemmon MA
FEBS Lett; 2004 Jul; 569(1-3):332-6. PubMed ID: 15225657
[TBL] [Abstract][Full Text] [Related]
33. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
34. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
Asp N; Pust S; Sandvig K
Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
[TBL] [Abstract][Full Text] [Related]
35. Higher-order association states of cellular ERBB3 probed with photo-cross-linkable aptamers.
Park E; Baron R; Landgraf R
Biochemistry; 2008 Nov; 47(46):11992-2005. PubMed ID: 18942860
[TBL] [Abstract][Full Text] [Related]
36. Synapse-associated expression of an acetylcholine receptor-inducing protein, ARIA/heregulin, and its putative receptors, ErbB2 and ErbB3, in developing mammalian muscle.
Moscoso LM; Chu GC; Gautam M; Noakes PG; Merlie JP; Sanes JR
Dev Biol; 1995 Nov; 172(1):158-69. PubMed ID: 7589796
[TBL] [Abstract][Full Text] [Related]
37. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
38. [Bacterial synthesis, purification, and solubilization of transmembrane segments of ErbB family members].
Goncharuk MV; Shul'ga AA; Ermoliuk IaS; Tkach EN; Goncharuk SA; Pustovalova IuE; Mineev KS; Bocharov ÉV; Maslennikov IV; Arsen'ev AS; Kirpichnikov MP
Mol Biol (Mosk); 2011; 45(5):892-902. PubMed ID: 22393787
[TBL] [Abstract][Full Text] [Related]
39. Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology.
Lund CV; Popkov M; Magnenat L; Barbas CF
Mol Cell Biol; 2005 Oct; 25(20):9082-91. PubMed ID: 16199884
[TBL] [Abstract][Full Text] [Related]
40. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development.
Kiguchi K; Bol D; Carbajal S; Beltrán L; Moats S; Chan K; Jorcano J; DiGiovanni J
Oncogene; 2000 Aug; 19(37):4243-54. PubMed ID: 10980598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
